Clinical observation on the efficacy of liraglutide combined with metformin in the treatment of type2 diabetes mellitus with non-alcoholic fatty liver

Abstract

Objective To observe the clinical efficacy of liraglutide combined with metformin in the treatment of newly diagnosed type2 diabetes mellitus (T2DM) accompanying non-alcoholic fatty liver disease (NAFLD). Methods 40 newly diagnosed patients with type 2 diabetes combined with fatty liver were randomly divided into observation group and control group. On the basis of lifestyle intervention, the observation group was given metformin 500 mg, oral, 3 times/d, Liraglutide Injection 1.8 mg, subcutaneous injection, 1 times/d, and the control group was given metformin 500 mg, orally, 3 times/d. The treatment process lasted for 12 weeks. Waist circumference, body mass index (BMI), fasting plasma glucose (FPG), 2 hour postprandial glucose (2 h PG), glycosylated hemoglobin A1c (HbA1c), alanine aminotransferase (ALT), aspartate transaminase (AST), glutamyl transpeptidase (GGT), total cholesterol (TC), triglyceride (TG), Transforming growth factor beta (TGF-β) and the degree of fatty liver were compared before and after treatment, and the adverse events were recorded. Results Compared with the control group, the degree of WC, BMI, FPG, 2 h PG, HbA1c, TG, TGF-beta and fatty liver were significantly improved in the observation group (P 0.05). Conclusions Liraglutide combined with metformin is a new kind of safe and effective treatment for T2DM accompanying NAFLD. Key words: Liraglutide/TU; Metformin/TU; Diabetes mellitus, type 2/CO/DT; Non-alcoholic fatty liver disease/CO/DT